AMAG Pharmaceuticals (AMAG) Sees Strong Trading Volume

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) saw an uptick in trading volume on Friday . 2,293,301 shares were traded during trading, an increase of 111% from the previous session’s volume of 1,088,499 shares.The stock last traded at $14.45 and had previously closed at $14.45.

A number of brokerages have recently weighed in on AMAG. Cantor Fitzgerald restated a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. B. Riley began coverage on AMAG Pharmaceuticals in a research note on Thursday, December 7th. They set a “neutral” rating and a $16.00 price target on the stock. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Morgan Stanley dropped their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Finally, Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $23.38.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Municipal Employees Retirement System of Michigan boosted its position in AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 510 shares during the last quarter. Hartford Investment Management Co. purchased a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $186,000. 361 Capital LLC purchased a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Cubist Systematic Strategies LLC purchased a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Finally, Aperio Group LLC purchased a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $198,000.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/17/amag-pharmaceuticals-amag-sees-strong-trading-volume.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

What are top analysts saying about AMAG Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit